Heron Therapeutics Inc (NASDAQ: HRTX) kicked off on Friday, down -5.81% from the previous trading day, before settling in for the closing price of $1.72. Over the past 52 weeks, HRTX has traded in a range of $1.04-$3.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 17.85% over the past five years. While this was happening, its average annual earnings per share was recorded 83.89%. With a float of $151.01 million, this company’s outstanding shares have now reached $151.70 million.
Let’s look at the performance matrix of the company that is accounted for 126 employees. In terms of profitability, gross margin is 67.55%, operating margin of -17.61%, and the pretax margin is -19.0%.
Heron Therapeutics Inc (HRTX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Heron Therapeutics Inc is 0.71%, while institutional ownership is 80.25%.
Heron Therapeutics Inc (HRTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 83.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.50% during the next five years compared to 20.01% growth over the previous five years of trading.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
Take a look at Heron Therapeutics Inc’s (HRTX) current performance indicators. Last quarter, stock had a quick ratio of 1.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Heron Therapeutics Inc (NASDAQ: HRTX) saw its 5-day average volume 18.08 million, a positive change from its year-to-date volume of 2.71 million. As of the previous 9 days, the stock’s Stochastic %D was 64.51%. Additionally, its Average True Range was 0.17.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 23.29%, which indicates a significant decrease from 60.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 149.52% in the past 14 days, which was higher than the 106.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6386, while its 200-day Moving Average is $2.4652. Nevertheless, the first resistance level for the watch stands at $1.6900 in the near term. At $1.7600, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8100. If the price goes on to break the first support level at $1.5700, it is likely to go to the next support level at $1.5200. Assuming the price breaks the second support level, the third support level stands at $1.4500.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
The company with the Market Capitalisation of 232.06 million has total of 152,095K Shares Outstanding. Its annual sales at the moment are 127,040 K in contrast with the sum of -110,560 K annual income. Company’s last quarter sales were recorded 32,810 K and last quarter income was -4,850 K.
